Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed a Current Report on Form 8-K dated February 28, 2025. The filing discloses the entry into a material definitive agreement involving a new revolving credit facility and significant changes to the composition of the Board of Directors.
Key Financial Metrics and Debt
- Debt Facility: Entered into a Revolving Loan Agreement with a maximum principal amount of $2,000,000.
- Interest Rate: 18% per annum, calculated on a 360-day year basis.
- Maturity: The entire payment amount is due on the first anniversary of the closing date (February 28, 2026).
- Use of Proceeds: General corporate purposes, including financing a Qualified Public Equity Offering.
- Financial Advisor Fees: $20,000 upfront fee paid to WestPark Capital, Inc., plus a 4% fee on each drawdown.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes
Board of Directors Reshuffle
As a condition of the loan closing, four directors resigned and three new directors were appointed:
- Resigned: Milton Brown, Bette Jacobs, Chris Senanayake, and Joshua Schafer.
- Appointed: George Scorsis, Joseph Tung, and Oleh Nabyt (designated by the Lender).
- Leadership Continuity: Dr. Anatoly Dritschilo remains Chairman of the Board; Steven Richards remains Chair of the Audit Committee.
Equity Offering Obligation
The Company is obligated to use reasonable best efforts to consummate an underwritten public offering of up to $6,000,000 of common stock or convertible securities as soon as practicable.
Restrictions on Share Repurchases
The agreement includes negative covenants prohibiting the Company from repurchasing its common stock, with limited exceptions for departing officers/directors (capped at $25,000 aggregate) and existing repurchase agreements (capped at $25,000 aggregate).
Outlook, Risks, and Contingencies
- Default Consequences: In the event of default, the Lender may accelerate the debt, requiring payment of 120% of the outstanding principal plus accrued interest and other costs.
- Reborrowing: Loans may be reborrowed after repayment, subject to terms, but no new loans may be requested after the 10th business day preceding the Maturity Date.
- Management Commentary: The filing does not provide specific management commentary on future operational performance beyond the obligation to pursue the equity offering.
Investor Verification Checklist
- Verify the exact amount drawn from the $2,000,000 revolving facility, as the filing only states the maximum capacity.
- Confirm the timeline and status of the required $6,000,000 Qualified Public Equity Offering.
- Review the full text of the Revolving Loan Agreement (Exhibit 10.1) for specific definitions of "Event of Default."
- Monitor the appointment of the new directors to specific board committees (Audit, Nomination, Compensation).
- Check for any subsequent filings regarding the $20,000 advisor fee and potential 4% drawdown fees.